Alerts will be sent to your verified email
Verify Email
LASA
|
Lasa Supergenerics
|
Gufic Biosciences
|
Bal Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-6.11 % | 26.14 % | 0.96 % |
|
5yr average Equity Multiplier
|
1.61 | 2.82 | 4.45 |
|
5yr Average Asset Turnover Ratio
|
0.76 | 1.1 | 0.94 |
|
5yr Avg Net Profit Margin
|
-5.47 % | 9.03 % | -0.14 % |
|
Price to Book
|
1.24 | 6.58 | 2.67 |
|
P/E
|
0.0 | 40.69 | 25.09 |
|
5yr Avg Cash Conversion Cycle
|
20.11 Days | -18.02 Days | 39.08 Days |
|
Inventory Days
|
51.19 Days | 77.22 Days | 108.27 Days |
|
Days Receivable
|
29.63 Days | 81.36 Days | 101.56 Days |
|
Days Payable
|
102.72 Days | 175.58 Days | 117.24 Days |
|
5yr Average Interest Coverage Ratio
|
-17.38 | 10.3 | 1.1 |
|
5yr Avg ROCE
|
1.63 % | 33.27 % | 13.66 % |
|
5yr Avg Operating Profit Margin
|
11.3 % | 17.37 % | 8.32 % |
|
5 yr average Debt to Equity
|
0.31 | 0.73 | 2.0 |
|
5yr CAGR Net Profit
|
26.27 % | 29.43 % | -7.48 % |
|
5yr Average Return on Assets
|
-3.66 % | 10.17 % | 0.26 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
53.65 % | 72.5 % | 51.23 % |
|
Share Pledged by Promoters
|
20.66 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-10.82 % | 7.37 % | 6.39 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | -0.94 % | 0.0 |
|
Lasa Supergenerics
|
Gufic Biosciences
|
Bal Pharma
|
|
|---|---|---|---|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|